Gilead can't escape antitrust suit centered on pay-for-delay deal with Cipla, judge says

A judge in California on Friday ruled that Gilead must face a lawsuit alleging anticompetitive conduct in its 2014 patent settlement with generic rival Cipla. In 2012, Cipla notified Gilead that it planned to market generic versions of antivirals Emtriva and Viread, prompting Gilead to sue the generics maker for infringement.